Results 71 to 80 of about 31,699 (207)

Prevalence of Antimicrobial Use in Small Animal Dermatology Referral Practices in the United States

Veterinary Dermatology, Volume 37, Issue 5, Page 581-591, October 2026.
ABSTRACT Background Antimicrobial resistance is a critical global health concern driven by antimicrobial use. Dermatological conditions are common reasons for antimicrobial prescriptions in small animal practice, yet data on prescribing patterns in veterinary dermatology referral settings are lacking. Hypothesis/Objectives To characterise the frequency,
Domenico Santoro, Emma R. Bollig, Jennifer L. Granick   +2 more
wiley   +1 more source

A Disproportionality Analysis of β‐lactam Antibiotic Related Blood and Lymphatic System Disorders Based on the FDA Adverse Event Reporting System Database

Health Science Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background and Aims β‐lactam antibiotics stand as the most profoundly impactful classes of antibacterial agents worldwide. Their widespread application has raised safety concerns over adverse events (AEs), such as blood and lymphatic system disorders (BLSDs).
Jing Liu, Min Zhang, Zongwei Tang, Xiaoxiao Wang, Li Mu, Wanyi Chen, Haichi Song   +6 more
wiley   +1 more source

Focused Update to International Consensus Recommendations for the Use of Prolonged‐Infusion Beta‐Lactam Antibiotics Among Severely Ill Adult Patients: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 9, September 2026.
ABSTRACT In 2023, international consensus recommendations suggested the use of prolonged‐infusion beta‐lactam antibiotics over short‐infusion dosing in severely ill adult patients to improve mortality or clinical cure, although the certainty of evidence was very low. With the availability of several new randomized controlled trials (RCTs), this focused
Lisa T. Hong, Alireza FakhriRavari, Marta Ulldemolins, Jason A. Roberts, Robert A. Bonomo, Marc H. Scheetz, on behalf of the Prolonged‐Infusion Beta‐Lactam Consensus Panel, Jacinda C. Abdul‐Mutakabbir, Mohammad H. Alshaer, Matteo Bassetti, Robert A. Bonomo, Kevin J. Downes, Alireza FakhriRavari, Mark Gilchrist, Lisa T. Hong, Jason A. Roberts, Marc H. Scheetz, Thomas Tängdén, Marta Ulldemolins, David C. Young   +19 more
wiley   +1 more source

Comparative pharmacokinetics of ampicillin-sulbactam combination in calves and sheep.

, 1994
The pharmacokinetics of ampicillin and sulbactam administered in combination were studied in calves and sheep. The animals were administered an aqueous solution of ampicillin/sulbactam (2:1, w/w) intravenously and intramuscularly at doses of 13.2 and 6.6
Sonzogni O, Villa R, Belloli C, MONTESISSA, CLARA, Carli S.   +4 more
core   +2 more sources

Identification of Potential Vaccine Strains of Escherichia coli Isolates From Diarrhoeic Calves

Veterinary Medicine and Science, Volume 12, Issue 5, September 2026.
This study aimed to identify vaccine candidate Escherichia coli strains isolated from diarrheic calves. Faecal samples collected from 500 calves were analysed, and E. coli strains were isolated and characterized phenotypically and genotypically. Antibiotic resistance profiles, virulence‐associated genes and MLVA genotyping were used to select 20 ...
Yasemin Erdoğan, Ediz Kağan Özgen, Murat Özmen, Elif Karadeniz Pütür, Nebahat Polat, Ersan Pütür, Mücahit Harmancı, Ercan Atalay, Ahmet Temur, Meryem Güloğlu, Lütfullah Celep, Seyda Cengiz, Mehmet Cemal Adıgüzel, Cihan Öz, Timur Gülhan, Alper Çiftci, Erhan Çiftgül   +16 more
wiley   +1 more source

Biliary pharmacokinetics of sulbactam plus ampicillin in humans

, 1986
The biliary pharmacokinetics of sulbactam and ampicillin was investigated in 19patients with normal liver function who were undergoing surgery of the biliary tract.
David L. Morris, Charles S. Robertson, Keith W. Brammer, Charanjeit S. Ubhi   +3 more
core   +1 more source

Hypersensitivity vasculitis induced by cefoperazone/sulbactam [PDF]

, 2003
Background Cefoperazone has not been reported to cause vasculitic complications before. Here, we report a case of hypersensitivity vasculitis associated with cefoperazone/sulbactam.
Ismail Islek, Katranci Ali O, Baris Sancar, Ender Ariturk, Ali O Katranci, Islek Ismail, Gurses Nuran, Sancar Baris, Nuran Gurses, Ariturk Ender   +9 more
core   +1 more source

A real‐world study on different initiation times and treatment durations of letermovir for cytomegalovirus prophylaxis after allogeneic haematopoietic stem cell transplantation

British Journal of Haematology, Volume 209, Issue 3, Page 1198-1207, September 2026.
Early letermovir initiation (day 0) after allogeneic haematopoietic stem cell transplantation (allo‐HSCT) reduced early cytomegalovirus (CMV) infection and delayed first CMV DNAemia compared with later starts. Extending prophylaxis to 200 days virtually eliminated late CMV reactivation and improved 1‐year overall survival, with no grade ≥3 drug‐related
Shiyu Chen, Zhihang Su, Xiaohan Zhang, Xiaoqing Li, Xin Du   +4 more
wiley   +1 more source

In vitro activity of cefoperazone and cefoperazone-sulbactam against carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa

, 2018
Chih-Cheng Lai,1 Chi-Chung Chen,2,3 Ying-Chen Lu,3 Yin-Ching Chuang,2,4 Hung-Jen Tang5,6 1Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan; 2Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan ...
Tang HJ, Lu YC, Chen CC, Lai CC, Chuang YC   +4 more
core  

Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem [PDF]

, 2002
Recent studies have highlighted the emergence of infections involving multiresistant Acinetobacter clinical isolates. Sulbactam offers direct antimicrobial activity against Acinetobacter species.
Levin, A.S.
core   +1 more source